ClinicalTrials.gg
RecruitingNCT06894433NESICH 2Updated Nov 17, 2026

Efficacy and Safety of NeuroEndoscopic Surgery for Large IntraCerebral Hemorrhage

An interventional study of neuroendoscopic surgery and craniotomy in Intracerebral Haemorrhage, sponsored by Southwest Hospital, China. Recruiting at 5 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Southwest Hospital, China · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 17, 2026Enrollment updatedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
384
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 123 studies in Cerebral Hemorrhage with a site in China — 59 open to participants now, 62 under way, 5 of them phase 3. Cerebral Hemorrhage · China.

Planned enrollment
26th of 77
384 · median 180
Started
2025
with 19 others
No phase
35 of 123
22 open now
Primary completion
2028-06
later than 43 of 61 live
Registered
94th of 123
by date
Lead sponsor
3 of 123
Southwest Hospital, China

Among the 123 studies in Cerebral Hemorrhage with a site in China, this one is the 26th largest by planned enrollment of the 77 interventional ones that give a count, is one of 20 that started in 2025, is one of 35 with no phase, reaches primary completion later than 43 of the 61 other live ones, and was the 94th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

59 of the 123 studies in Cerebral Hemorrhage with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 59 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 123 studies in Cerebral Hemorrhage with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, controlled clinical trial comparing neuroendoscopic hematoma removal to craniotomy in the treatment of large intracerebral hemorrhage.

Read the detailed description

Previous retrospective studies have demonstrated that neuroendoscopic surgery, compared to conventional craniotomy, significantly reduces operative duration and intraoperative blood loss, enhances hematoma evacuation rates, and improves postoperative outcomes, including neurological recovery, activities of daily living, and quality of life in patients with large cerebral hemorrhage. However, there is a paucity of prospective randomized controlled trials evaluating the efficacy of different surgical techniques for intracerebral hemorrhage. To address this gap, the investigators propose a multicenter, randomized, controlled clinical trial to compare the safety and efficacy of neuroendoscopic surgery versus craniotomy, aiming to provide evidence-based guidance for surgical decision-making in cerebral hemorrhage management.

03

Conditions studied

  • Intracerebral Haemorrhage

Browse trials for

Keywords

  • intracerebral hemorrhage
  • neuroendoscopic
  • craniotomy
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years old, male or female;
  2. The time between onset and admission to the first diagnostic CT is within 24 hours (for no bystanders and the time of onset is unknown, the time of the last known patient in good condition is used);
  3. Patients with supratentorial intracerebral hemorrhage who have obvious space-occupying effect caused by hematoma (midline structure shift > 6mm) or hematoma volume ≥ 45ml and require emergency surgery (including patients with signs of cerebral herniation such as decreased or dilated pupillary light reflex on one side);
  4. Before randomization, GCS score was 5-14, NIHSS score was ≥6;
  5. mRS Before onset: 0-1 score;
  6. Randomization within 24 hours after the first diagnostic CT;
  7. The patient or family members are informed and voluntarily sign the ;

Exclusion criteria

Exclusion Criteria:

  1. The clinical diagnosis is caused by cerebral aneurysm, cerebrovascular malformation, moyamoya disease, brain trauma, brain tumor, massive cerebral infarction hemorrhage transformation, coagulation dysfunction, etc.;
  2. Thalamic hemorrhage, primary ventricular hemorrhage;
  3. count \<75×109/L, > 1.4;
  4. Patients with advanced cerebral hernia (such as dilated bifidus and no light reflex) or unstable vital signs cannot tolerate surgery;
  5. Irreversible brain stem impairment (eye fixation, bilateral pupil dilation), GCS≤4 points;
  6. Any history of parenchyma or other intracranial subarachnoid, subdural or epidural blood and surgical history in the past 30 days;
  7. Patients with severe advanced cognitive impairment (such as AD) or who are not expected to complete the follow-up plan as required;
  8. Complicated with other serious diseases: including respiratory, circulation, digestion, urinary, endocrine, immune and blood systems;
  9. Pregnant or breastfeeding women, or those who expect to become pregnant within one year;
  10. are participating in other clinical trials (excluding: observational studies that do not involve intervention, natural history and/or epidemiological studies).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
384 participants (estimated)

Study arms

  • Experimental
    Experimental Arm

    Neuroendoscopic Surgery to remove intracranial hematoma

    Procedure: neuroendoscopic surgery

  • Active comparator
    Control Arm

    Craniotomy to remove intracranial hematoma

    Procedure: craniotomy

Interventions

  • Procedureneuroendoscopic surgery

    Subjects will receive Neuroendoscopic Surgery followed by standard medical management

  • Procedurecraniotomy

    Subjects will receive Craniotomy followed by standard medical management

06

What researchers measure

Primary outcomes

  1. The proportion of patients with Modified Rankin Scale (mRS) score 0-3

    Functional outcome (comparing the intervention group to the control), assessed with the modified Rankin Scale (mRS) at 6 months.The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death.

    Time frame: 180 days

Secondary outcomes

  1. mRS Shift Analysis of Neurological Improvement Between the Two Groups

    The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death.

    Time frame: 180 days

  2. mortality

    All cause mortality from onset to 180 days

    Time frame: 30 days, 90 days and 180 days

  3. Assessment of cognitive function with Mini-Mental State Examination (MMSE)

    The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function.

    Time frame: 90 days and 180 days

  4. Length of ICU

    Duration of stay in the ICU

    Time frame: Number of days from admission, up to 180 days

  5. Length of hospitalization

    Duration of stay in the hospital

    Time frame: Number of days from admission to discharge, up to 180 days

  6. The proportion of patients with Modified Rankin Scale (mRS) score 0-3

    Functional outcome (comparing the intervention group to the control), assessed with the modified Rankin Scale (mRS) at 6 months.The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death.

    Time frame: 30 days and 90 days

  7. Operation duration

    The length of the operation

    Time frame: From the beginning to the end of the surgery

  8. Peroperative bleeding

    The amount of blood lost during surgery

    Time frame: During surgery

  9. Intraoperative blood transfusion volume

    Intraoperative blood transfusion volume

    Time frame: During surgery

  10. Incidence of rebleeding and infection

    Incidence of rebleeding and infection in the two groups within 3 days, 7 days, and 30 days after randomization

    Time frame: 3 days, 7 days, and 30 days after randomization

  11. Incidence of complications

    Incidence of other common complications within 180 days (epilepsy, hydrocephalus, pneumonia, gastrointestinal bleeding, deep vein thrombosis, cardiovascular and cerebrovascular events, etc.)

    Time frame: 180 days

  12. Incidence of adverse events and serious adverse events

    Incidence of adverse events and serious adverse events in the two groups within 180 days

    Time frame: 180 days

07

Study locations

5 of 5 sites recruiting
08

References and documents

Publications

  • Beck J, Fung C, Strbian D, Butikofer L, Z'Graggen WJ, Lang MF, Beyeler S, Gralla J, Ringel F, Schaller K, Plesnila N, Arnold M, Hacke W, Juni P, Mendelow AD, Stapf C, Al-Shahi Salman R, Bressan J, Lerch S, Hakim A, Martinez-Majander N, Piippo-Karjalainen A, Vajkoczy P, Wolf S, Schubert GA, Hollig A, Veldeman M, Roelz R, Gruber A, Rauch P, Mielke D, Rohde V, Kerz T, Uhl E, Thanasi E, Huttner HB, Kallmunzer B, Jaap Kappelle L, Deinsberger W, Roth C, Lemmens R, Leppert J, Sanmillan JL, Coutinho JM, Hackenberg KAM, Reimann G, Mazighi M, Bassetti CLA, Mattle HP, Raabe A, Fischer U; SWITCH study investigators. Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial. Lancet. 2024 Jun 1;403(10442):2395-2404. doi: 10.1016/S0140-6736(24)00702-5. Epub 2024 May 15. PubMed 38761811 ↗
  • Pradilla G, Ratcliff JJ, Hall AJ, Saville BR, Allen JW, Paulon G, McGlothlin A, Lewis RJ, Fitzgerald M, Caveney AF, Li XT, Bain M, Gomes J, Jankowitz B, Zenonos G, Molyneaux BJ, Davies J, Siddiqui A, Chicoine MR, Keyrouz SG, Grossberg JA, Shah MV, Singh R, Bohnstedt BN, Frankel M, Wright DW, Barrow DL; ENRICH trial investigators; ENRICH Trial Investigators. Trial of Early Minimally Invasive Removal of Intracerebral Hemorrhage. N Engl J Med. 2024 Apr 11;390(14):1277-1289. doi: 10.1056/NEJMoa2308440. PubMed 38598795 ↗
  • Correction to: ICES (Intraoperative Stereotactic Computed Tomography-Guided Endoscopic Surgery) for Brain Hemorrhage: A Multicenter Randomized Controlled Trial. Stroke. 2017 Nov;48(11):e335. doi: 10.1161/STR.0000000000000153. No abstract available. PubMed 29061841 ↗
  • Hanley DF, Thompson RE, Rosenblum M, Yenokyan G, Lane K, McBee N, Mayo SW, Bistran-Hall AJ, Gandhi D, Mould WA, Ullman N, Ali H, Carhuapoma JR, Kase CS, Lees KR, Dawson J, Wilson A, Betz JF, Sugar EA, Hao Y, Avadhani R, Caron JL, Harrigan MR, Carlson AP, Bulters D, LeDoux D, Huang J, Cobb C, Gupta G, Kitagawa R, Chicoine MR, Patel H, Dodd R, Camarata PJ, Wolfe S, Stadnik A, Money PL, Mitchell P, Sarabia R, Harnof S, Barzo P, Unterberg A, Teitelbaum JS, Wang W, Anderson CS, Mendelow AD, Gregson B, Janis S, Vespa P, Ziai W, Zuccarello M, Awad IA; MISTIE III Investigators. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 2019 Mar 9;393(10175):1021-1032. doi: 10.1016/S0140-6736(19)30195-3. Epub 2019 Feb 7. PubMed 30739747 ↗
  • Greenberg SM, Ziai WC, Cordonnier C, Dowlatshahi D, Francis B, Goldstein JN, Hemphill JC 3rd, Johnson R, Keigher KM, Mack WJ, Mocco J, Newton EJ, Ruff IM, Sansing LH, Schulman S, Selim MH, Sheth KN, Sprigg N, Sunnerhagen KS; American Heart Association/American Stroke Association. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2022 Jul;53(7):e282-e361. doi: 10.1161/STR.0000000000000407. Epub 2022 May 17. No abstract available. PubMed 35579034 ↗
  • Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA, Selim MH, Woo D; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015 Jul;46(7):2032-60. doi: 10.1161/STR.0000000000000069. Epub 2015 May 28. PubMed 26022637 ↗
  • Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MD, Barer DH; STICH investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005 Jan 29-Feb 4;365(9457):387-97. doi: 10.1016/S0140-6736(05)17826-X. PubMed 15680453 ↗
  • Teo KC, Fong SM, Leung WCY, Leung IYH, Wong YK, Choi OMY, Yam KK, Lo RCN, Cheung RTF, Ho SL, Tsang ACO, Leung GKK, Chan KH, Lau KK. Location-Specific Hematoma Volume Cutoff and Clinical Outcomes in Intracerebral Hemorrhage. Stroke. 2023 Jun;54(6):1548-1557. doi: 10.1161/STROKEAHA.122.041246. Epub 2023 May 22. PubMed 37216445 ↗
  • Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke. 1993 Jul;24(7):987-93. doi: 10.1161/01.str.24.7.987. PubMed 8322400 ↗
  • Sondag L, Schreuder FHBM, Boogaarts HD, Rovers MM, Vandertop WP, Dammers R, Klijn CJM; Dutch ICH Surgery Trial Study Group, part of the CONTRAST consortiumdagger. Neurosurgical Intervention for Supratentorial Intracerebral Hemorrhage. Ann Neurol. 2020 Aug;88(2):239-250. doi: 10.1002/ana.25732. Epub 2020 Apr 30. PubMed 32239722 ↗
  • Ma L, Hu X, Song L, Chen X, Ouyang M, Billot L, Li Q, Malavera A, Li X, Munoz-Venturelli P, de Silva A, Thang NH, Wahab KW, Pandian JD, Wasay M, Pontes-Neto OM, Abanto C, Arauz A, Shi H, Tang G, Zhu S, She X, Liu L, Sakamoto Y, You S, Han Q, Crutzen B, Cheung E, Li Y, Wang X, Chen C, Liu F, Zhao Y, Li H, Liu Y, Jiang Y, Chen L, Wu B, Liu M, Xu J, You C, Anderson CS; INTERACT3 Investigators. The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial. Lancet. 2023 Jul 1;402(10395):27-40. doi: 10.1016/S0140-6736(23)00806-1. Epub 2023 May 25. PubMed 37245517 ↗
  • Pinho J, Costa AS, Araujo JM, Amorim JM, Ferreira C. Intracerebral hemorrhage outcome: A comprehensive update. J Neurol Sci. 2019 Mar 15;398:54-66. doi: 10.1016/j.jns.2019.01.013. Epub 2019 Jan 14. PubMed 30682522 ↗
  • van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010 Feb;9(2):167-76. doi: 10.1016/S1474-4422(09)70340-0. Epub 2010 Jan 5. PubMed 20056489 ↗
  • GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):439-458. doi: 10.1016/S1474-4422(19)30034-1. Epub 2019 Mar 11. PubMed 30871944 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2028, 36 months after the start.

Of 77 non-industry interventional studies with no phase under Cerebral Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 75. This study's planned 36 months is close to that.

Counting every sponsor, half of 85 studies reached it within 38 months; a quarter within 19 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 25, 2025
StartActual
Jun 1, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 1 site removed
Show 4 added (4 China)
  • Southwest Hospital · Chongqing, China
  • Wuwei People's Hospital · Wuwei, China
  • Wuzhou Workers' Hospital · Wuzhou, China
  • Siping Central People's Hospital · Siping, China
Show 1 removed
  • Southwest Hospital · Chongqing, China
Nov 17, 2026
Enrollment
280→384
Nov 17, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPatients with supratentorial intracerebral hemorrhage (supratentorial intracerebral hemorrhagewho have obvious space-occupying effect caused by hematoma (supratentorial intracerebral hemorrhagemidline structure shift > 6mm) whoseor hematoma volume is ≥50ml or whose hematoma produces obvious space occupying effect≥ 45ml and requiresrequire emergency surgery (including patients with signs of cerebral hernia signsherniation such as retardingdecreased or dilatation ofdilated pupillary light reflex ofon one pupilside);
Exclusion criteria
  • EditedPlatelet count <10075×109/L, INR > 1.4;
Nov 17, 2026
Secondary outcomes
1 edited, 4 added, 3 removed
What changed in the outcomes
  • ChangedBefore Modified Rankin Scale (mRS) ScoreNow mRS Shift Analysis of Neurological Improvement Between the Two GroupsTime frame: 180 days
  • AddedIntraoperative blood transfusion volumeTime frame: During surgery
  • AddedIncidence of rebleeding and infectionTime frame: 3 days, 7 days, and 30 days after randomization
  • AddedIncidence of complicationsTime frame: 180 days
  • AddedIncidence of adverse events and serious adverse eventsTime frame: 180 days
  • RemovedGlasgow Outcome Scale Extended (GOS-E)Time frame: 180 days
  • RemovedQuality of life measured with the 5-level EQ-5D (EQ-5D-5L)Time frame: 30 days and 180 days
  • RemovedThe proportion of patients with Modified Rankin Scale (mRS) score 0-2Time frame: 180 days
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    4 sites added, 1 site removed
    Show 4 added (4 China)
    • Southwest Hospital · Chongqing, China
    • Wuwei People's Hospital · Wuwei, China
    • Wuzhou Workers' Hospital · Wuzhou, China
    • Siping Central People's Hospital · Siping, China
    Show 1 removed
    • Southwest Hospital · Chongqing, China
    Enrollment 280→384
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatients with supratentorial intracerebral hemorrhage (supratentorial intracerebral hemorrhagewho have obvious space-occupying effect caused by hematoma (supratentorial intracerebral hemorrhagemidline structure shift > 6mm) whoseor hematoma volume is ≥50ml or whose hematoma produces obvious space occupying effect≥ 45ml and requiresrequire emergency surgery (including patients with signs of cerebral hernia signsherniation such as retardingdecreased or dilatation ofdilated pupillary light reflex ofon one pupilside);
    Exclusion criteria
    • EditedPlatelet count <10075×109/L, INR > 1.4;
    Secondary outcomes 1 edited, 4 added, 3 removed
    What changed in the outcomes
    • ChangedBefore Modified Rankin Scale (mRS) ScoreNow mRS Shift Analysis of Neurological Improvement Between the Two GroupsTime frame: 180 days
    • AddedIntraoperative blood transfusion volumeTime frame: During surgery
    • AddedIncidence of rebleeding and infectionTime frame: 3 days, 7 days, and 30 days after randomization
    • AddedIncidence of complicationsTime frame: 180 days
    • AddedIncidence of adverse events and serious adverse eventsTime frame: 180 days
    • RemovedGlasgow Outcome Scale Extended (GOS-E)Time frame: 180 days
    • RemovedQuality of life measured with the 5-level EQ-5D (EQ-5D-5L)Time frame: 30 days and 180 days
    • RemovedThe proportion of patients with Modified Rankin Scale (mRS) score 0-2Time frame: 180 days
    + 4 other changes: verification date, date precision, oversight details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06894433
Lead sponsor
Southwest Hospital, China
Responsible party
Rong Hu, MD (Director of Department of Neurosurgery, Southwest Hospital, China) — Principal investigator
First posted
Mar 25, 2025
Start date
Jun 1, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Rong Hu, MD
Contact
huchrong@aliyun.com
8615123917123
Hua Feng, MD
Contact
fenghua201818@aliyun.com
8613708321681
Rong Hu, MD
study chair · PLA Army Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion